BACKGROUND: Sarcopenia is defined as the loss of skeletal muscle mass and is a modifiable condition that affects between 27 to 61% of patients with inflammatory bowel disease (IBD). Socia...
BACKGROUND:
Ustekinumab (UST) is a monoclonal antibody against the p40 subunit of IL-12/23. It is approved for the treatment of moderate to severe Crohn's disease (CD) and Ulc...
BACKGROUND:
Intestinal strictures are a complication of the inflammatory bowel diseases (IBD, including ulcerative colitis (UC) and Crohn’s disease (CD)) that can lead to bowe...
BACKGROUND:
Immune checkpoint inhibitors (ICIs) have significantly changed the oncologic treatment landscape for a wide array of cancers over the past few decades. While these...
BACKGROUND:
Hospitalizations for Black patients with inflammatory bowel disease (IBD) have increased in recent decades though our understanding of disease behavior in Black pa...
CASE:
Inflammatory Bowel Disease (IBD) is becoming more common in an increasingly diverse population. Exposure history is important, especially when prescribing immunosuppress...
BACKGROUND:
Inflammatory Bowel Disease (IBD) prevalence is rising. Quality of life (QOL) in chronic illness is affected by various physical and psychosocial factors. Recent st...
BACKGROUND:
Ethical principles in the field of medicine have become increasingly relevant during the COVID-19 pandemic, during which practitioners are required to provide care...
BACKGROUND:
Current inflammatory bowel disease (IBD) therapies are limited by incomplete efficacy, loss of response, side effects and high costs. Vagal nerve stimulation (VNS)...
BACKGROUND:
Colitis describes inflammation in the colon and is classified into defined diseases: Inflammatory bowel disease (IBD), Microscopic colitis, Ischemic colitis and In...